Endocrine tumors: The evolving role of positron emission tomography in diagnosis and management

Journal of Endocrinological Investigation

Volumn 33, Issue 1, 2010, Pages 54-60

  Naji, M ^a   Hodolic, M ^b   El Refai, S ^c   Khan, S ^a   Marzola, M C ^d   Rubello, D ^d   Al Nahhas, A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c Kasr Elaini Hospital   (Egypt)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Endocrine tumors; Functional imaging; PET

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 3 METHYLSPIPERONE C 11; 5 HYDROXYTRYPTOPHAN C 11; CATECHOLAMINE; EPHEDRINE C 11; FLUORODEOXYGLUCOSE F 18; FLUORODOPAMINE F 18; FLUOROETHYL SPIPERONE F 18; FLUOROETHYLESTER F 18; GALLIUM 68; HYDROCORTISONE; HYDROXYEPHEDRINE C 11; L DIHYDROXYPHENYLALANINE F 18; METHIONINE C 11; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; METOMIDATE C 11; OCTREOTIDE; PENTETREOTIDE IN 111; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; SELEGILINE; STEROID 11BETA MONOOXYGENASE; SUCCIMER TC 99M; TETA OCTERIOTIDE CU 64; UNCLASSIFIED DRUG;

ADRENAL SCINTISCANNING; ADRENAL TUMOR; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; CYCLOTRON; DIAGNOSTIC ACCURACY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG UPTAKE; ENDOCRINE TUMOR; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HYPOPHYSIS TUMOR; INTERMETHOD COMPARISON; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PARATHYROID TUMOR; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY HYPERALDOSTERONISM; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER; THYROID MEDULLARY CARCINOMA;

ADRENAL GLAND NEOPLASMS; ADRENAL MEDULLA; CARCINOMA, NEUROENDOCRINE; CATECHOLAMINES; CUSHING SYNDROME; ENDOCRINE GLAND NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; ORGANOMETALLIC COMPOUNDS; PARATHYROID NEOPLASMS; PITUITARY NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77950535280     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6561     Document Type: Review

References (67)

1. Khan S, Lloyd C, Szyszko T, Win Z, Rubelte D, Al-Nahhas A. PET imaging in endocrine tumours. Minerva Endocrinol 2008, 33: 41-52.
2. 18F FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing's syndrome. Eur J Endocrinol 2005, 152: 521-525
3. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004, 25: 568-580
4. Chong S, Lee KS, Kim HY, et al. Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. Radiographics 2006, 26: 1811-1826
5. Leboulleux S, Dromain C, Bonniaud G, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 2006, 91: 920-925
6. Blake MA, Slattery JM, Kalra MK, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy initial experience. Radiology 2006, 238: 970-977
7. 11C-metomidate. J Nucl Med 2000, 41: 275-82;
8. Comment in J Nucl Med 2000, 41: 1933-4.
9. Kumar R, Abass A, Fanti S. Adrenocortical positron emission tomography/PET-CT imaging. PET Clinics 2007, 2: 331-339
10. Wadsak W, Mitterhauser M, Rendl G, et al. 18F FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging 2006, 33: 669-672
11. Blake M, Kalra M, Maher M, et al. Pheochromocytoma: an imaging chameleon. Radiographics 2004, 24: S87-99.
12. Goldstein DS, Eisenhofer G, Flynn J A, Wand G, Pacak K. Diagnosis and localization of phaeochromocytoma. Hypertension 2004, 43: 907-910
13. Sohaib SA, Rockall AG, Reznek RH. Imaging functional adrenal disorders. Best Pract Res Clin Endocrinol Metab 2005, 19: 293-310.
14. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging 2004, 48: 150-163
15. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007, 14: 569-585
16. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endoc Relat Cancer 2007, 14: 587-599
17. Mottaghy FM, Reske SN. Functional imaging of neuroendocrine tumours with PET. Pituitary 2006, 9: 237-242
18. 11C Hydroxyephedrine PET. Radiology 2004, 230: 423-428
19. Shulkin BL, Wieland DM, Schwaiger M, et al. PET scanning with hydroxyephedrine: an approach to the location of phaeochromocytoma. J Nucl Med 1992, 33: 1125-1131
20. Prasad V, Ambrosini V, Alavi A, Fanti S, Baum R. PET/CT in neuroendocrine tumors: evaluation of receptor status and metabolism. PET Clinics 2007, 2: 351-375
21. 18R-fluorodopamine positron emission tomography. J Clin Endocrinol Metab 2003, 88: 637-41.
22. Khan S, Win Z, Szyszko T, et al. PET imaging of phaeochromocytoma. PET Clinics 2007, 2: 341-349
23. 18R-Auorodopamine positron emission tomography in the localization of adrenal phaeochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol 2007, 156: 483-7.
24. 18F DOPA whole body PET-initial results. Radiology 2002, 222: 507-512
25. 131I]metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Endocrinol Metab 2003, 88: 4083-4087
26. Intenzo C, Jabbour S, Lin H, et al. Scintigraphic imaging of body neuroendocrine tumors. Radiographics 2007, 27: 1355-1369
27. 18F-DOPA PET for the assessment of NET patients. Nucl Med Commun 2008, 29: 415-417
28. Nanni C, Rubello D, Al-Nahhas A, Fanti S. Clinical PET in oncology: not only FDG. Nucl Med Commun 2006, 27: 685-688
29. Dalgorf D, Higgins K M, Ehrlich L PET/CT fusion technology: its role in managing recurrent, well-differentiated thyroid cancer. Can JSurg 2008, 51: E21-2.
30. Grünwald F, Kalicke T, Feine U, et al. Fluorine-18- fluorodeoxyglucose positron emission tomography in thyroid cancer result of a multicentre study. Eur J Nucl Med 1999, 26: 1547-1552
31. Joensuu H, Ahonen A. Imaging of Metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987, 28: 910-914
32. Plotkin M, Hautzel H, Krause B J, et al. Implication of 2-18fluor-2-deoxyglucose positron emission tomography in the follow up Hurthle cell thyroid cancer. Thyroid 2002, 12: 155-161
33. Dionigi G, Castano P, Bertolini V, et al. Simultaneous medullary and papillary thyroid cancer, two case reports. J Med Case Reports 2007, 1: 133.
34. Urhan M, Alavi A, Nanni C. The evolving role of positron emission tomography in patients with medullary thyroid carcinoma. PET Clinics 2007, 2: 305-311
35. 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007, 48: 501-507
36. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002, 43: 66-71.
37. Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007, 92: 4185-4190
38. Urhan M, Mavi A, Alavi A, Nanni C. Positron emission tomography and thyroid cancer. PET Clinics 2007, 2: 295-304.
39. Grassetto G, Alavi A, Rubello D. PET and parathyroid. PET Clinics 2007, 2: 385-393
40. Neumann DR, Esselstyn CB, Maclntyre WJ, Go RT, Obuchowski NA, Chen EQ, Licata AA. Comparison of FDG-PET and sestamibi-SPECT in primary hyperparathyroidism. J Nucl Med 1996, 37: 1809-1815
41. Neumann DR, Esselstyn CB, Kim EY. Recurrent postoperative parathyroid carcinoma: FDG-PET and sestamibi-SPECT findings. J Nucl Med 1996, 37: 2000-2001
42. 11C Methionine positron emission tomography for patients with persistent or recurrent hyperparathyroidism after surgery. Eur J Endocrinol 1998, 139: 195-7.
43. Sundin A, Johansson C, Hellman P, et al. PET and parathyroid L-[carbon-11] methionine accumulation in hyperparathyroidism. J Nucl Med 1996, 37: 1766-1770
44. 11C-methionine positron emission tomography. Nucl Med Commun 2005, 26: 133-136
45. Otto D, Boemer A, Hofmann M, et al. Pre-operative localisation of hyperfunctional parathyroid tissue with 11 C-methionine PET. Eur J Nucl Med MoI Imaging 2004, 31: 1405-1412
46. Eriksson B, Orlefors H, Oberg K, Sundin A, Bergström M, Langström B. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 2005, 19: 311-324
47. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004, 25: 458-511.
48. Klöppel G, Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2005, 19: 507-517
49. Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab 2005, 19: 213-227
50. 123l-Tyr3]- octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20: 716-731
51. 111ln-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med 2000, 41: 459-462
52. 18F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clinical Cancer Research 2004, 10: 3593-3606
53. Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, Rubello D. Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res 2007, 27: 4087-4094
54. Nanni C, Rubello D, Al-Nahhas A, Fanti S. Clinical PET in oncology: not only FDG. Nucl Med Commun 2006, 27: 685-688
55. Hofmann M, Maecke H, Borner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminery data. Eur J Nucl Med 2001, 28: 1751-1757
56. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Try3-octeriotide PET in neuroendocrine tumours: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007, 48: 508-518
57. Junik R, Drobik P, Matkowski B, Kobus-Btachnio K. The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET). Adv Med Sci 2006, 51: 66-68
58. Hoegerle S, Altehoefer C, Ghanem N, et al. Whole-body 18-F-DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology 2001, 220: 373-380
59. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008, 35: 1431-1438
60. Ahlstrom H, Eriksson B, Bergström M, Bjurling P, Langström B, Oberg K. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995, 195: 333-337
61. Oriefors H, Sundin A, Ahlstrom H, et al. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol 1998, 16: 2534-2541
62. 11C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005, 90: 3392-400.
63. 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008, 26: 1489-1495
64. 64Cu-TETA- octreotide as a PET imaging agent for patients with neuroendocrine tumours. J Nucl Med 2001, 42: 213-221
65. Muhr C. Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology 2006, 83: 205-210
66. de Herder WW, Reijs AE, Feelders RA, et al. Diagnostic imaging of dopamine receptors in pituitary adenomas. Eur J of Endocrinol 2007, 156 (Suppl 1): S53-6.
67. Koo C W, Bhargava P, Rajagopalan V, Ghesani M, Sims-Childs H, Kagetsu N J. Incidental detection of clinically occult pituitary adenoma on whole-body FDG PET imaging. Clin Nucl Med 2006, 31: 42-43